Drugs / Ezutromid
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02383511 | Feb → Aug 2015 | Duchenne muscular dystrophy | Summit Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02056808 | Nov 2013 → May 2014 | Duchenne muscular dystrophy | Summit Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02858362 | Jun 2016 → Apr 2018 | Duchenne muscular dystrophy | Summit Therapeutics | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ezutromid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02858362 ↗ |
| Known as | BMN 195 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773683 ↗ |
| Known as | SMT C1100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02383511 ↗ |
| Modality | Small molecule | — CHEMBL1773683 ↗ |
| Route | Oral | “Multiple Oral Dose” NCT02056808 ↗ |
| Target | UTRN | “Utrophin modulator” CHEMBL1773683 ↗ |